Breast Cancer, Triple-Negative Breast Cancer
Conditions
Keywords
anti-PD-1 antibody, VEGFR2 TKI
Brief summary
This is a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) for neoadjuvant treatment of patients with triple-negative breast cancer and \>10% tumor-infiltrating lymphocytes (TILs) in baseline breast tumors. We will enroll 58 subjects (Simon's two stage design). The study is designed to evaluate the efficacy and safety of camrelizumab in combination with apatinib in the neoadjuvant treatment of TNBC with a high proportion of TILs.
Detailed description
This a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial to assess the efficacy and safety of camrelizumab combination with apatinib in female patients age of 18 to 70 with TNBC, and baseline tumor-infiltrating lymphocytes \> 10%. The number of patients to be included is 58 patients (Simon's two stage design). The primary objective is to assess the pCR. All enrolled patients will be treated with camrelizumab 200mg (iv. 3mg/kg for patient whose weight is below 50kg) on day 1 of each 21-day cycle, and apatinib 250mg daily (po, d1-d21).
Interventions
DRUGAnti-PD-1 monoclonal antibody
Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
DRUGVEGFR2 Tyrosine Kinase Inhibitor
Apatinib 250 mg, po, qd
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients sign the written informed consent. 2. Women aged 18-70. 3. Patients with histologically confirmed operable invasive breast cancer (T1cN1-2 or T2-4N0-2)［ER-negative(IHC\<1%), PR-negative(IHC\<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］. 4. Percentage of tumor-infiltrating lymphocytes \>10% in baseline breast tumor. 5. Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard. 6. No previous breast cancer-related treatment, including chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy. 7. Patients can swallow pills. 8. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1. 9. Patients with a life expectancy of at least 12 weeks. 10. The patient's blood test results prior to enrollment met the following criteria： • Hb≥90g/L; • Plt≥100\^9/L; • Serum albumin ≥3g/dL; • Neutrophils≥1.5\^9/L; • TSH≤ normal upper limit (ULN); * ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN); * TBIL ≤ULN (total bilirubin ≤1.5 ULN in Gilbert's syndrome or liver metastasis subjects); * ALT and AST ≤1.5 ULN (liver metastases ≤3 ULN); * AKP≤ 2.5 ULN; * Renal function within 7 days before the first administration: serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min. 11. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment.
Exclusion criteria
1. Combination of other malignancies or previous malignancies other than breast cancer within the last 5 years, except for basal cell carcinoma or flat cell carcinoma of the skin or carcinoma in situ of the uterine cervix that has been adequately controlled by treatment. 2. Those who are not suitable for immunotherapy in combination with active infection. 3. The combination of severe non-malignant disease that would affect patient compliance or put the patient at risk. 4. Concomitant with other antineoplastic therapy or are participating in other clinical trials. 5. Male breast cancer, bilateral breast cancer or inflammatory breast cancer. 6. Patients with dementia, mental abnormality or any mental illness that prevents understanding of the informed consent form. 7. Patients with history of allergic reaction or contraindication to the use of any drug component of this trial. 8. Patients with any active autoimmune disease or a history of autoimmune disease (e.g., the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or whose asthma has completely resolved in childhood and does not require any intervention in adulthood may be included; (Patients with asthma that requires medical intervention with bronchodilators cannot be included). 9. Have cardiac clinical symptoms or disease that are not well controlled, such as: (1) NYHA class 2 or higher heart failure; (2) Unstable angina pectoris; (3) Myocardial infarction within 1 year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention. 10\. Urine routine suggestive of urine protein ≥++, or confirmed 24-hour urine protein amount ≥1.0g. 11\. Known presence of hereditary or acquired bleeding and thrombotic tendencies (e.g., hemophiliacs, coagulation disorders, thrombocytopenia, hypersplenism, etc.). 12\. Patients with congenital or acquired immune deficiencies (e.g., HIV-infected individuals). 13\. Live vaccines administered less than 4 weeks prior to study drug administration or possibly during the study. 14\. Active tuberculosis. 15. Patients have received oral or intravenous antibiotic therapy within 2 weeks prior to neoadjuvant therapy. 16\. Major surgical procedure within 4 weeks prior to the start of study treatment or anticipated need for major surgical procedure during the course of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological Complete Remission (pCR) rate | After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks | pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Breast Conservation Rate | Up to approximately 24-26 weeks | The percentage of patients who undergo breast-conserving surgery after neo-adjuvant therapy. |
| Incidence of Treatment-Emergent Adverse Events | From the first drug administration to within 90 days for the last dose | Adverse events/serious adverse events. |
| Objective Response Rate (ORR) | After neoadjuvant study treatment and surgery, up to approximately 24-26 weeks | The propotion of subjects with CR or PR according to RECIST v1.1. |
| Overall Survival (OS) | Up to approximately 8 years | defined as the time from randomization to death due to any cause. |
| Frequencies of Biomarkers | Up to approximately 24-26 weeks | Biomarkers (including tumor/stromal PD-L1, stromal PD-1, tumor-infiltrating lymphocytes and tumor-infiltrating B cells, eg). |
| Event-Free Survival (EFS) | Up to approximately 8 years | Event-free survival (EFS) defined as the time from recruitment until documented disease recurrence, progression, or death from any cause in all participants. EFS events covered under disease recurrence will include local, regional, or distant recurrence and contralateral breast cancer. Ipsilateral or contralateral in situ disease and second primary non-breast cancers will not be counted as EFS events. |
Countries
China
Contacts
Primary ContactJieqiong Liu, MD,PhD
Outcome results
None listed